<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11715">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02057406</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00043654</org_study_id>
    <secondary_id>R34MH097034-01A1</secondary_id>
    <nct_id>NCT02057406</nct_id>
  </id_info>
  <brief_title>Omega 3 for Treatment of Depression in Patients With Heart Failure</brief_title>
  <acronym>OCEAN</acronym>
  <official_title>Omega 3 for Comorbid Depression and Heart Failure Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Data and Safety Monitoring Board</authority>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Omega 3 supplements will improve depressive symptoms to a greater extent than placebo in
      heart failure patients with moderate to severe major depressive disorder.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to determine whether (Hypothesis 1a) and how
      (Hypothesis 1b) the two omega 3 supplements will reduce depressive symptoms in heart failure
      (HF) patients with moderate-to-severe major depressive disorder (MDD).

      Hypothesis 1a: Omega 3 supplements will improve depressive symptoms to a greater extent than
      placebo; Hypothesis 1b: Pure eicosapentaenoic acid (EPA) will be superior to the EPA:
      docosahexaenoic acid (DHA) 2:1 in depression improvement.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in Hamilton Depression Rating Scale (HDRS) score</measure>
    <time_frame>Baseline through week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Red Blood Cell/Plasma EPA</measure>
    <time_frame>Baseline through week 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>400/200 EPA/DHA fish oil 2 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>400/200 EPA/DHA fish oil 2 grams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Almost pure EPA 2 grams</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Almost pure EPA 2 grams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Matched placebo corn oil capsules</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matched placebo corn oil capsules</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>400/200 EPA/DHA fish oil 2 grams</intervention_name>
    <arm_group_label>400/200 EPA/DHA fish oil 2 grams</arm_group_label>
    <other_name>400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>An almost pure EPA 2 grams</intervention_name>
    <arm_group_label>Almost pure EPA 2 grams</arm_group_label>
    <other_name>An almost pure Eicosapentaenoic acid 2 grams</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matched placebo corn oil capsules</intervention_name>
    <arm_group_label>Matched placebo corn oil capsules</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult male and female patients, age greater than or equal to 21 years

          -  Diagnosis of Major Depressive Disorder determined by the DSM-IV-TR criteria with a
             Hamilton Depression Rating Scale Score greater than or equal to 18*

          -  New York Heart Association Class greater than or equal to II

               -  For patients with with left ventricular ejection fraction greater than 40 %,
                  abnormal brain natriuretic peptide and/or previous hospitalization due to heart
                  failure is also required

               -  For inpatients, the Hamilton Depression Rating Scale scores need to be remain at
                  18 or above for two weeks following the discharge

        Exclusion Criteria:

          -  Significant cognitive impairment, indicated as a Mini-Mental State Examination (MMSE)
             total score of 23 or lower

          -  History of alcohol or other drug dependence within the past 90 days

          -  Severe physical disability (visual, sensory, or motor) that may interfere with
             psychiatric assessment

          -  History or presence of psychoses, bipolar disorder, and/or severe personality
             disorders

          -  Life-threatening comorbidity with the likelihood of 50% mortality in one year

          -  Active suicidal ideations

          -  Current use of antipsychotic medications or psychotropic medications except SSRIs and
             /or benzodiazepine

          -  Female patients who have a positive pregnancy test or are lactating.  If female
             patients are of childbearing potential, they must use an effective and accepted means
             of contraception, such as oral contraceptives or a double-barrier method (condom and
             diaphragm) to protect against pregnancy

          -  Documented history of hypersensitivity or intolerance to omega 3 products; or use of
             omega 3 supplement for greater than or equal to 3 months at an equivalent or greater
             dose of the proposed study

          -  Treatment with electroconvulsive therapy (ECT) or transcranial magnetic stimulation
             (TMS) within 90 days*

          -  Uncorrected hypothyroidism or hyperthyroidism

          -  Treatment with any investigational agent within 1 month before randomization

          -  Acute coronary syndrome, i.e., MI or unstable angina, revascularization procedure
             within the preceding month, or planned cardiac surgery within 3 months
             postrandomization

               -  The exclusion of patients who received ECT or TMS within 90 days is adopted from
                  other depression-intervention trials and meant to eliminate confounders.  It is
                  believed that the effects of ECT on mood and cognition may last for a couple of
                  months, and duration of TMS effects is poorly known and may be similar to the
                  ECT intervention.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Jiang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jerry L Kirchner, BS, CCRP</last_name>
    <phone>919-668-7818</phone>
    <email>jerry.kirchner@duke.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wei Jiang, MD</last_name>
    <phone>919-668-0762</phone>
    <email>wei.jiang@duke.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Leslie Stewart</last_name>
      <email>leslie_stewart@med.unc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Amanda Lee</last_name>
      <email>amanda_garrand@med.unc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Kirkwood F. Adams, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Wilson, BA</last_name>
      <phone>919-681-4367</phone>
      <email>j.wilson@duke.edu</email>
    </contact>
    <contact_backup>
      <last_name>Wei Jiang, MD</last_name>
      <phone>919-668-0762</phone>
      <email>wei.jiang@duke.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Wei Jiang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bridget Rooney</last_name>
      <email>bridget.rooney@jefferson.edu</email>
    </contact>
    <contact_backup>
      <last_name>Suzanne Adams</last_name>
      <email>suzanne.adams@jefferson.edu</email>
    </contact_backup>
    <investigator>
      <last_name>David J. Whellan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 12, 2014</lastchanged_date>
  <firstreceived_date>February 5, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
